Chainshorts
Finance

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

Regeneron has agreed to a drug pricing deal with Trump, offering free access to a new hearing-loss therapy. This move aligns with recent industry trends of pricing concessions. The deal aims to improve access and reduce costs for patients, marking a significant shift in pharmaceutical pricing strategies amid ongoing healthcare debates.

Read to earn +1
Share on XShare on Telegram

More in Finance

Finance

Inside Complaints About Alex Cooper’s Podcast Empire

Alex Cooper, host of Call Her Daddy, faces internal challenges within her podcast empire, with some issues reportedly linked to her husband. The article, published by Bloomberg, highlights ongoing complaints and internal struggles as of April 2026. Specific financial figures or dates are not provided, but the report underscores internal conflicts affecting her business operations.

Bloomberg MarketsApr 23source ↗
Finance

United’s CEO Is Here to Buy Your Struggling Airline

United Airlines CEO Scott Kirby aims to make the airline the best in history, despite challenges like merger talks, rising fuel prices, and internal conflicts. The article highlights his ambitious vision amid ongoing industry turbulence, but specific financial figures or dates are not provided. The focus remains on United’s strategic efforts to strengthen its position in the airline industry.

Bloomberg MarketsApr 23source ↗
Finance

US Taps Kirkland & Ellis for Advice on Spirit Airlines Rescue

The US government engaged law firm Kirkland & Ellis to advise on a potential rescue deal for Spirit Aviation Holdings Inc., signaling ongoing efforts to stabilize the airline amid financial challenges, according to sources familiar with the matter. The move indicates the government’s active role in supporting strategic industries during economic uncertainty.

Bloomberg MarketsApr 23source ↗
Finance

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration plans to reclassify marijuana as Schedule III, easing research restrictions without legalizing or altering federal penalties. This policy shift could facilitate scientific studies and medical research on cannabis, representing a major change in federal drug policy. The move aims to balance regulation with research needs, impacting future cannabis legislation.

CNBC BusinessApr 23source ↗
Finance

Jane Street Seeks Dismissal of Terraform Insider-Trading Suit

Jane Street has filed to dismiss a lawsuit alleging insider trading related to Terraform Labs' $40 billion crypto crash. The firm denies the claims and seeks to have the case dismissed. The lawsuit accuses Jane Street of trading on inside information before the collapse, but no court ruling has been made as of April 2026.

Bloomberg MarketsApr 23source ↗
Finance

Fed, FDIC Finalize Changes Easing Community Bank Leverage Ratio

US regulators finalized changes to ease the community bank leverage ratio, building on previous efforts from the Trump administration. The move aims to reduce capital requirements for small banks, potentially increasing lending capacity and supporting economic growth. The adjustments are part of ongoing regulatory reforms to balance safety and financial flexibility.

Bloomberg MarketsApr 23source ↗
All Finance